Michael Augenbraun
Overview
Explore the profile of Michael Augenbraun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu M, Gerig L, Mehta C, Musonge-Effoe J, Alvarez J, Ofotokun I, et al.
Clin Infect Dis
. 2025 Feb;
PMID: 39899358
Background: The impact of integrase strand-transfer inhibitors (INSTIs) on steatotic liver disease in women with HIV (WWH) is unknown. Methods: Using data collected in the Women's Interagency HIV Study from...
2.
Lahiri C, Mehta C, Yang Q, Maramba T, Musonge-Effoe J, Yang C, et al.
Clin Infect Dis
. 2024 Sep;
PMID: 39324701
Background: Sex-specific, long-term, body weight change in persons with HIV (PWH) following switch to regimens containing integrase strand-transfer inhibitors (INSTIs) is unknown. Methods: We compared PWH enrolled in the MACS/WIHS...
3.
4.
Yang A, Huang V, Samaroo-Campbell J, Augenbraun M
Infect Prev Pract
. 2023 Jul;
5(3):100296.
PMID: 37520840
Methods: This was a retrospective case-control study of patients with isolates recovered from January 2019 to December 2020. MDR was defined as non-susceptibility to at least one agent in three...
5.
Edmonds A, Haley D, Edwards J, Ramirez C, French A, Tien P, et al.
Clin Infect Dis
. 2023 Apr;
77(2):258-264.
PMID: 37021689
Background: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) is well tolerated, cost-effective, and yields high sustained virologic response rates, yet it has remained financially inaccessible to many patients....
6.
Lea A, Leyden W, Sofrygin O, Marafino B, Skarbinski J, Napravnik S, et al.
Clin Infect Dis
. 2023 Mar;
76(10):1727-1734.
PMID: 36861341
Background: People with human immunodeficiency virus (HIV) (PWH) may be at increased risk for severe coronavirus disease 2019 (COVID-19) outcomes. We examined HIV status and COVID-19 severity, and whether tenofovir,...
7.
Peters B, Moon J, Hanna D, Kutsch O, Fischl M, Moran C, et al.
J Infect Dis
. 2021 Aug;
225(4):675-685.
PMID: 34448873
Summary: In women with HIV, higher activation and exhaustion of CD4+ T cells were associated with risk of non-HIV-related mortality during a median of 13.3 years of follow-up, independent of...
8.
Norin A, Mendoza R, Augenbraun M, Das B
Hum Immunol
. 2021 Jul;
82(10):713-718.
PMID: 34303556
A disproportionate incidence of death has occurred in African Americans (Blacks) in the United States due to COVID-19. The reason for this disparity is likely to be multi-factorial and may...
9.
French A, Grennan D, Daubert E, Seaberg E, Peters M, Augenbraun M, et al.
AIDS
. 2021 Mar;
35(9):1433-1438.
PMID: 33710024
Objective: Eradication of hepatitis C virus (HCV) in HIV disease decreases liver and non-liver-related morbidity and mortality. Elevated markers of monocyte/macrophage activation (soluble CD163 and sCD14) are associated with excess...
10.
Mendoza R, Fyke W, Daniel D, Gabutan E, Das B, Bajaj H, et al.
Hum Immunol
. 2021 Feb;
82(4):255-263.
PMID: 33640208
Early in the SARS-CoV-2 pandemic, convalescent plasma (CP) therapy was proposed as a treatment for severely ill patients. We conducted a CP treatment protocol under the Mayo Clinic Extended Access...